cbx-12
Peptideexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 3, 2021 (NCT04902872)
Timeline
Indications
Studied for
- Appendiceal Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Payload
- exatecan
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06730100 | Phase 2 | May 23, 2025 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT06315491 | Phase 2 | Aug 31, 2024 | Cybrexa Therapeutics |
| NCT05691517 | Phase 1 | Feb 3, 2024 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT04902872 | Phase 1/Phase 2 (Phase 2) | May 3, 2021 | Cybrexa Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cybrexa Therapeutics | For profit | 2 | 2 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 2 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1